Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

Despite recent advances in the development of tools to predict immunogenicity risk of biotherapeutic molecules, the ability of a protein to elicit the formation of anti-drug antibodies (ADA) remains one of the most common causes for termination of clinical development programs. In this study, we use...

Descripción completa

Detalles Bibliográficos
Autores principales: Bivi, Nicoletta, Moore, Terry, Rodgers, George, Denning, Heather, Shockley, Travis, Swearingen, Craig A., Gelfanova, Valentina, Calderon, Boris, Peterson, Daniel A., Hodsdon, Michael E., Siegel, Robert W., Higgs, Richard E., Konrad, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601536/
https://www.ncbi.nlm.nih.gov/pubmed/31099718
http://dx.doi.org/10.1080/19420862.2019.1612699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601536/
https://www.ncbi.nlm.nih.gov/pubmed/31099718
http://dx.doi.org/10.1080/19420862.2019.1612699

Ejemplares similares